JP7442439B2 - Ｋｄｍ４阻害剤 - Google Patents

Ｋｄｍ４阻害剤 Download PDF

Info

Publication number
JP7442439B2
JP7442439B2 JP2020503253A JP2020503253A JP7442439B2 JP 7442439 B2 JP7442439 B2 JP 7442439B2 JP 2020503253 A JP2020503253 A JP 2020503253A JP 2020503253 A JP2020503253 A JP 2020503253A JP 7442439 B2 JP7442439 B2 JP 7442439B2
Authority
JP
Japan
Prior art keywords
kdm4
cells
cancer
tumor
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020503253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515645A (ja
JP2020515645A5 (https=
Inventor
シューレ，ローランド
メッツガー，エリック
Original Assignee
アルベルト－ルートヴィヒ－ユニバーシティー フライブルク
セルジーン クオンティセル リサーチ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルベルト－ルートヴィヒ－ユニバーシティー フライブルク, セルジーン クオンティセル リサーチ，インク． filed Critical アルベルト－ルートヴィヒ－ユニバーシティー フライブルク
Publication of JP2020515645A publication Critical patent/JP2020515645A/ja
Publication of JP2020515645A5 publication Critical patent/JP2020515645A5/ja
Application granted granted Critical
Publication of JP7442439B2 publication Critical patent/JP7442439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020503253A 2017-03-30 2018-03-27 Ｋｄｍ４阻害剤 Active JP7442439B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762478785P 2017-03-30 2017-03-30
US62/478,785 2017-03-30
US201762513875P 2017-06-01 2017-06-01
US62/513,875 2017-06-01
PCT/US2018/024624 WO2018183370A2 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Publications (3)

Publication Number Publication Date
JP2020515645A JP2020515645A (ja) 2020-05-28
JP2020515645A5 JP2020515645A5 (https=) 2021-05-06
JP7442439B2 true JP7442439B2 (ja) 2024-03-04

Family

ID=63678220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503253A Active JP7442439B2 (ja) 2017-03-30 2018-03-27 Ｋｄｍ４阻害剤

Country Status (6)

Country Link
US (3) US20200039938A1 (https=)
EP (1) EP3600301B1 (https=)
JP (1) JP7442439B2 (https=)
ES (1) ES2991090T3 (https=)
TW (1) TWI814723B (https=)
WO (1) WO2018183370A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100997A1 (es) * 2014-06-25 2016-11-16 Quanticel Pharmaceuticals Inc Derivados de piridina como inhibidores de histona demetilasa
US20200039938A1 (en) 2017-03-30 2020-02-06 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
CN113876953B (zh) * 2020-07-02 2022-12-09 中国科学院上海营养与健康研究所 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用
WO2022217100A1 (en) * 2021-04-09 2022-10-13 Tachyon Therapeutics, Inc. Treatment of cancer with kdm4 inhibitors
CA3227684A1 (en) * 2021-08-18 2023-02-23 Jr. Richard M. Heid Process for preparing histone demethylase inhibitors
CA3242035A1 (en) * 2021-12-23 2023-06-29 Gowri Sukumar Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
CN120225189A (zh) * 2022-09-21 2025-06-27 细胞基因公司 组蛋白去甲基化酶抑制剂3-({[(4r)-7-{甲基[4-(丙烷-2-基)苯基]氨基}-3，4-二氢-2h-1-苯并吡喃-4-基]甲基}氨基)吡啶-4-甲酸l-赖氨酸盐的结晶形式

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2015200709A1 (en) 2014-06-25 2015-12-30 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
GB0307643D0 (en) 2003-04-02 2003-05-07 Cyclacel Ltd Markers
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7898712B2 (en) 2008-06-27 2011-03-01 Lockheed Martin Corporation Risley integrated steering module
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
US20140163041A1 (en) * 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013143597A1 (en) 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
WO2014089368A1 (en) 2012-12-05 2014-06-12 Bio-Rad Laboratories, Inc Methods for polymerase chain reaction copy number variation assays
EP2928471B1 (en) 2012-12-06 2020-10-14 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US8969343B2 (en) 2012-12-19 2015-03-03 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014139324A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Tetracyclic bromodomain inhibitors
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
US9890434B2 (en) * 2014-03-19 2018-02-13 National Tsing Hua University Method for identifying compound for inhibiting an activity of a histone lysine demethylase
EP3126345A1 (en) * 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
SI3137169T1 (sl) 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
EP3397617A4 (en) * 2015-12-28 2019-05-22 Celgene Quanticel Research, Inc. HISTONDEMETHYLASEINHIBITOREN
US20200039938A1 (en) 2017-03-30 2020-02-06 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
JP6781095B2 (ja) 2017-03-31 2020-11-04 エア・ウォーター株式会社 化合物半導体基板
WO2019083594A1 (en) 2017-08-21 2019-05-02 The General Hospital Corporation COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2022217100A1 (en) 2021-04-09 2022-10-13 Tachyon Therapeutics, Inc. Treatment of cancer with kdm4 inhibitors
CA3227684A1 (en) 2021-08-18 2023-02-23 Jr. Richard M. Heid Process for preparing histone demethylase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2015200709A1 (en) 2014-06-25 2015-12-30 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Breast Cancer: Basic and Clinical Research，2016年，Vol. 10，pp. 169-175

Also Published As

Publication number Publication date
ES2991090T3 (es) 2024-12-02
WO2018183370A3 (en) 2018-12-20
EP3600301A4 (en) 2020-08-12
WO2018183370A2 (en) 2018-10-04
TW201840537A (zh) 2018-11-16
US20180290977A1 (en) 2018-10-11
EP3600301A2 (en) 2020-02-05
TWI814723B (zh) 2023-09-11
EP3600301B1 (en) 2024-07-03
US20240076271A1 (en) 2024-03-07
JP2020515645A (ja) 2020-05-28
US20200039938A1 (en) 2020-02-06
US12516024B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
JP7442439B2 (ja) Ｋｄｍ４阻害剤
JP2022017495A (ja) 癌を治療するための併用療法
JP2022050631A (ja) Ｔｇ０２によるがん治療
CN111225903B (zh) 谷氨酰胺酶抑制剂疗法
CN118459413A (zh) 用于治疗癌症的组合物和方法
JP7719135B2 (ja) 微小残存がんを治療する方法
US9573899B2 (en) USP7 inhibitor compounds and methods of use
CN114288294A (zh) 用于治疗或者预防血液癌症的化合物和方法
BR112013028095B1 (pt) Uso de inibidores de csf-1r para o tratamento de tumores cerebrais
CN121889152A (zh) 用于治疗费城染色体阳性血癌的sos1抑制剂
US9649313B2 (en) Use of ITK inhibitors for the treatment of cancer
JP2025503385A (ja) メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化
KR20240051953A (ko) Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법
TR201815685T4 (tr) Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
WO2018089967A1 (en) Inhibitors of cancer invasion, attachment, and/or metastasis
EP3999053A1 (en) Method of treating neoplastic diseases with a cdc42-specific inhibitor
CN115607674B (zh) Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
US20210238140A1 (en) Compounds for Targeting Cancer Stem Cells
CN114984007B (zh) Pradx-ezh2小分子抑制剂及其在制备肿瘤治疗药物中的用途
JP2020061973A (ja) 大腸癌患者の選択方法
WO2025174952A1 (en) Treatment of cancers via rna-binding motif protein 39 (rbm39) degradation
EA049995B1 (ru) Соединения, ингибирующие изоформу альфа pi3k, и способы лечения онкологического заболевания
CN105078983A (zh) 阿司咪唑、其盐或溶剂合物在制备预防和/或治疗恶性淋巴瘤的药物中的用途
JP2023547108A (ja) γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する
Lin et al. Targeting BMI1 and MCL1 for Lung Adenocarcinoma Treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240220

R150 Certificate of patent or registration of utility model

Ref document number: 7442439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150